References
- World Health Organization. Maternal Mortality [Internet]. 2015 November. Available from: http://www.who.int/mediacentre/factsheets/fs348/en/ [last accessed 18 Dec 2015]
- Sekizawa A, Purwosunu Y, Matsuoka R, et al. Recent advances in non-invasive prenatal DNA diagnosis through analysis of maternal blood. J Obstet Gynaecol Res 2007;33:747–64
- Staff AC. Circulating predictive biomarkers in preeclampsia. Pregnancy Hypertens 2011;1:28–42
- Sibai BM. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol 2006;30:16–19
- McIntire DD, Leveno KJ. Neonatal mortality and morbidity rates in late preterm births compared with births at term. Obstet Gynecol 2008;111:35–41
- Polsani S, Phipps E, Jim B. Emerging new biomarkers of preeclampsia. Adv Chronic Kidney Dis 2013;20:271–9
- Buhimschi IA, Zhao G, Funai EF, et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am J Obstet Gynecol 2008;199:551 e1–16
- Trifonova EA, Gabidulina TV, Ershov NI, et al. Analysis of the placental tissue transcriptome of normal and preeclampsia complicated pregnancies. Acta Naturae 2014;6:71–83
- Bianchi DW. Circulating fetal DNA: its origin and diagnostic potential-a review. Placenta 2004;25:S93–101
- Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485–7
- Tounta G, Kolialexi A, Papantoniou N, et al. Non-invasive prenatal diagnosis using cell-free fetal nucleic acids in maternal plasma: Progress overview beyond predictive and personalized diagnosis. EPMA J 2011;2:163–71
- Sifakis S, Zaravinos A, Maiz N, et al. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol 2009;201:472 e1–7
- Chim SS, Tong YK, Chiu RW, et al. Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proc Natl Acad Sci U S A 2005;102:14753–8
- Chan KC, Ding C, Gerovassili A, et al. Hypermethylated RASSF1A in maternal plasma: a universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006;52:2211–18
- Wright CF, Burton H. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Hum Reprod Update 2009;15:139–51
- Ohashi Y, Miharu N, Honda H, et al. Quantitation of fetal DNA in maternal serum in normal and aneuploid prenancies. Hum Genet 2001;108:123–7
- Zhong XY, Holzgreve W, Hahn S. Circulatory fetal and maternal DNA in pregnancies at risk and those affected by preeclampsia. Ann N Y Acad Sci 2001;945:138–40
- Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007;120:3163–72
- Papantoniou N, Bagiokos V, Agiannitopoulos K, et al. RASSF1A in maternal plasma as a molecular marker of pre-eclampsia. Prenat Diagn 2013;33:682–7
- Kim MJ, Kim SY, Park SY, et al. Association of fetal-derived hypermethylated RASSF1A concentration in placenta-mediated pregnancy complications. Placenta 2013;34:57–61
- Zejskova L, Jancuskova T, Kotlabova K, et al. Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma–next step toward reliable non-invasive prenatal diagnostics. Exp Mol Pathol 2010;89:241–7
- Zhao F, Wang J, Liu R, et al. Quantification and application of the placental epigenetic signature of the RASSF1A gene in maternal plasma. Prenat Diagn 2010;30:778–82
- Patel RR, Steer P, Doyle P, et al. Does gestation vary by ethnic group? A London-based study of over 122,000 pregnancies with spontaneous onset of labour. Int J Epidemiol 2003;33:107–13
- Buck Louis GM, Grewal J, Albert PS, et al. Racial/ethnic standards for fetal growth: the NICHD Fetal Growth Studies. Am J Obstet Gynecol 2015;213:449.e1–1
- Alberry MS, Maddocks DG, Hadi MA, et al. Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. Am J Obstet Gynecol 2009;200:98 e1–6
- Vora NL, Johnson KL, Basu S, et al. A multifactorial relationship exists between total circulating cell-free DNA levels and maternal BMI. Prenat Diagn 2012;32:912–14
- Lapaire O, Volgmann T, Grill S, et al. Significant correlation between maternal body mass index at delivery and in the second trimester, and second trimester circulating total cell-free DNA levels. Reprod Sci 2009;16:274–9
- Liao GJ, Gronowski AM, Zhao Z. Non-invasive prenatal testing using cell-free fetal DNA in maternal circulation. Clin Chim Acta 2014;428:44–50
- Smith SC, Baker PN. Placental apoptosis is increased in post-term pregnancies. Br J Obstet Gynaecol 1999;106:861–2
- Sharp AN, Heazell AE, Crocker IP, Mor G. Placental apoptosis in health and disease. Am J Reprod Immunol 2010;64:159–69